Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone [12]

Eye

Volumn 21, Issue 8, 2007, Pages 1128-1130

  Ekdawi, N S ^a   Bakri, S J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

AGED; CASE REPORT; CENTRAL RETINA VEIN OCCLUSION; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; FOLLOW UP; HUMAN; LETTER; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA MACULA EDEMA; RISK BENEFIT ANALYSIS; VISUAL IMPAIRMENT;

EID: 34547941833     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702903     Document Type: Letter

References (4)

1. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: An evidence-based systematic review. Ophthalmology 2007; 114(3): 507-519. 524.
2. Goff MJ, Jumper JM, Yang SS, Fu AD, Johnson RN, McDonald HR et al. Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina 2006; 26 8): 896-901.
3. Gregon NZ, Rosenfeld PJ, Puliafito CA, Flynn Jr HW, Lee JE, Mavrofrides EC et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006; 26(8): 889-895.
4. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yammuzzi LA, Fisher YL et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina 2006; 26(3): 279-284.